Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Voyager Therapeutics, Inc. (Nasdaq: VYGR) SEC filings page on Stock Titan brings together the company’s public regulatory disclosures, including current reports on Form 8-K that furnish financial results, corporate updates, and investor presentations. As a Delaware-incorporated public company with common stock listed on the Nasdaq Global Select Market, Voyager files with the U.S. Securities and Exchange Commission to report material information related to its biotechnology business focused on neurological diseases.
Through these filings, readers can access details on Voyager’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities. The company’s 8-K filings often attach press releases that describe quarterly financial and operating results, cash runway expectations, and progress across its pipeline, including Alzheimer’s disease programs such as the anti-tau antibody VY7523 and tau silencing gene therapy VY1706, as well as partnered gene therapy programs with Neurocrine Biosciences and collaborations with Novartis and other partners.
Voyager’s filings also reference its TRACER™ AAV capsid discovery platform, next-generation capsids designed for blood-brain barrier penetration, and collaborations such as the small molecule discovery and license option agreement with Transition Bio targeting TDP-43 in ALS and frontotemporal dementia. Forward-looking statements and risk disclosures in these documents outline uncertainties related to regulatory decisions, clinical development, collaboration milestones, intellectual property, and the company’s ability to fund operations.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major financial metrics, pipeline updates, and collaboration terms. Users can follow new 8-Ks and other SEC reports in real time, review historical filings for context on Voyager’s evolution, and connect these disclosures to the company’s news flow and stock performance.
Voyager Therapeutics, Inc. reported fourth quarter and full year 2025 financial and operating results, highlighting pipeline progress in Alzheimer’s disease, intravenous gene therapies, and its Voyager NeuroShuttle™ platform. Collaboration revenue for 2025 was $40.4 million, down from $80.0 million in 2024, while net loss widened to $119.7 million from $65.0 million.
The company ended 2025 with $201.7 million in cash, cash equivalents, and marketable securities and expects this to fund operations into 2028, assuming planned expenses and anticipated collaboration reimbursements and interest income. Management also notes potential additional non-dilutive development milestones of up to $2.4 billion under existing collaborations.
Voyager Therapeutics, Inc. files its annual report describing a genetics-driven pipeline targeting neurological diseases using AAV gene therapy and a non-viral NeuroShuttle platform. Programs focus on Alzheimer’s, Friedreich’s ataxia, Parkinson’s, Gaucher disease, Huntington’s and other CNS conditions, combining wholly owned assets with major pharma collaborations.
The company highlights Alzheimer’s candidates VY1706, a tau-silencing gene therapy expected to enter clinical testing in 2026, and VY7523, an anti-tau antibody now in a multiple-dose Phase 1 trial. Voyager reports more than $500.0 million in aggregate non-dilutive funding from partners and potential future milestones of up to $6.8 billion, alongside royalties, across Novartis, Neurocrine, Alexion/AstraZeneca and Transition Bio deals.
As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was approximately $144.2 million, and there were 59,599,375 common shares outstanding as of March 2, 2026. The filing also outlines extensive intellectual property around TRACER capsids, tau therapies, GBA1, frataxin and Huntington’s disease.
Voyager Therapeutics COO & CBO Robin Swartz reported an automatic tax-related sale of 6,458 common shares. On
The sale was executed under a durable automatic sale instruction adopted on
Voyager Therapeutics, Inc. director and President & CEO Alfred Sandrock reported an open-market sale of common stock tied to tax withholding. He sold 14,197 shares of common stock at a weighted average price of $3.79 per share in transactions on February 24, 2026.
The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units on February 21, 2026, and is described as not a discretionary trade. Following these transactions, Sandrock directly holds 484,060 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. Chief Financial Officer Nathan D. Jorgensen reported an open-market sale of 4,668 shares of common stock at a weighted average price of $3.77 per share. After this non-discretionary sell-to-cover tax transaction, he holds 151,416 shares directly.
Voyager Therapeutics’ Chief Scientific Officer, Carter Todd Alfred, reported an automatic sale of 4,174 shares of common stock at a weighted average price of $3.76 per share.
The shares were sold under a pre-set instruction to cover tax withholding tied to restricted stock units vesting on February 21, 2026, and he continues to hold 145,718 shares directly.
Notice of proposed resale under Rule 144 by a holder associated with restricted stock vesting. The filing lists a planned sale of 4,174 common shares tied to restricted stock vesting on
VYGR reports a planned sale of 6,458 common shares under Rule 144 tied to restricted stock vesting on
The filing also discloses prior dispositions by Robin E. Swartz in the past three months: 4,569 shares sold on
VYGR reports a restricted stock vesting of 14,197 common shares effective
The filing also discloses recent open‑market dispositions by Alfred W. Sandrock Jr.: 12,192 shares sold on